Roche pays $160M up front for diabetes tech; Rexahn's antidepressant flunks trial;

 @FierceBiotech: Roche: Still looking for deals in 2010. Report | Follow @FierceBiotech

 @JohnCFierce: This Reuters story from Canada makes the U.S. IPO market for biotechs look hot--and it isn't. Report | Follow @JohnCFierce

> Rexahn Pharmaceuticals' antidepressant Serdaxin has failed an early mid-stage trial. Rexahn release

> Roche has agreed to pay shareholders $160 up front and up to $40 million to buy diabetes pump developer Medingo from Elron Electronics. The move is part of Roche's plan to increase its diabetes offerings. Roche report

> Baxter's Alzheimer's treatment Gammagard showed early promise in an Phase II trial. Baxter release

> Avraham Pharmaceuticals has raised $9 million from Clal Biotechnology Industries, Yissum Technology Transfer Company of the Hebrew University of Jerusalem, the Pontifax Fund LP, Prof. Marta Weinstock-Rosin of the Hebrew University and other investors. Report

> Organ-replacement developer Tengion 's initial public offering last week is more evidence the Philadelphia region has a leading position in developing cutting-edge drugs and therapies, a top industry official said Tuesday. Report

> Connecticut has put up half the $700,000 raised by a Branford bioscience startup that is harvesting for medical use the chemical compounds produced by soil microbes. Report

And Finally... Although printing organs and tissues may sound like science fiction, Wake Forest researchers have developed a device akin to the an office inkjet printer that can spray skin cells directly onto burn victims, quickly protecting the wound and serving as an alternative to skin grafts. Report

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.